Sunitinib is still one of the standard treatments in advanced ccRCC patients, researchers searched the GEO database and microarray data in sunitinib-resistant RCC tumors and demonstrated that MAPK/ERK pathway was excessive activating in sunitinib-resistance RCC tumors25. Here, MAPK1 is linked to nonpapillary renal cell carcinoma.